<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213135</url>
  </required_header>
  <id_info>
    <org_study_id>25643</org_study_id>
    <nct_id>NCT00213135</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)</brief_title>
  <acronym>CLARITY</acronym>
  <official_title>A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if cladribine tablets are a safe and effective
      treatment for relapsing-remitting multiple sclerosis (RRMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, three-arm, placebo-controlled, multi-center study. The
      study includes a pre-study evaluation period (up to 28 days prior to the start of treatment);
      an initial treatment period from Week 1 to 48; and a re-treatment period during Week 49 to
      96.

      During the initial treatment period (Week 1 to 48), eligible subjects are equally randomized
      by a central randomization system to receive either a) cladribine at a low dose (0.875
      milligram per kilogram per course [mg/kg/course] for two courses plus placebo for two
      courses); b) cladribine at a high dose (0.875 mg/kg/course for four courses); or c) placebo
      (four courses). During the re-treatment period (Weeks 49 to 96), subjects received either a)
      cladribine at a low dose (0.875 mg/kg/course for two courses); or b) placebo (two courses).

      For all randomized subjects, there is a rescue option of treatment with RebifÂ® (interferon
      beta-1a 44 microgram (mcg) given subcutaneously three times a week), if the subject
      experienced more than one qualifying relapse, and/or experienced a sustained increase in
      their EDSS score of greater than or equal to (&gt;=) 1 point, or &gt;=1.5 points if baseline EDSS
      score is 0, (over a period of three months or greater), during a calendar year beginning at
      Week 24.

      To maintain the blind, there is a treating physician who view clinical laboratory results and
      assess adverse events and safety information, and an independent blinded evaluating physician
      who will perform neurological exams. A central neuroradiology center, also blinded to
      treatment, will assess magnetic resonance imaging (MRI) evaluations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Qualifying Relapse Rate</measure>
    <time_frame>Week 96</time_frame>
    <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Relapse-free Participants</measure>
    <time_frame>Week 96</time_frame>
    <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the EDSS or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disability Progression</measure>
    <time_frame>Baseline up to Week 96</time_frame>
    <description>Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Tenth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Combined Unique (CU) Lesions, Active Time Constant 2 (T2) Lesions, and Active Time Constant 1 (T1) Gadolinium-Enhanced (Gd+) Lesions Per Participant Per Scan</measure>
    <time_frame>Week 96</time_frame>
    <description>Mean Number of CU lesions, active T2 lesions, and active T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1326</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Cladribine 5.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 3.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine 5.25 mg/kg</intervention_name>
    <description>Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine 5.25 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine 3.5 mg/kg</intervention_name>
    <description>Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine 3.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, between 18 and 65 years of age (inclusive, at time of informed
             consent)

          -  Has definite MS according to the McDonald criteria

          -  Has relapsing-remitting disease with 1 or more relapses within 12 months prior to
             Study Day 1

          -  Must have been clinically stable and not has a relapse within 28 days prior to Study
             Day 1

          -  Has MRI consistent with MS at the pre-study evaluation according to the Fazekas
             criteria

          -  Has a EDSS score from 0 to 5.5, inclusive

          -  Weighed between 40-120 kilogram (kg), inclusive

          -  If female, she must:

               1. be post-menopausal or surgically sterilized; or

               2. uses a hormonal contraceptive, intra uterine device, diaphragm with spermicide,
                  or condom with spermicide, for the duration of the study; and

               3. be neither pregnant nor breast-feeding

          -  If male, he must be willing to use contraception to avoid pregnancies

          -  Be willing and able to comply with study procedures for the duration of the study

          -  Voluntarily provides written informed consent, and for United states of America (USA)
             sites only, a subject authorization under Health Insurance Portability and
             Accountability Act (HIPAA)

        Exclusion Criteria:

          -  Has secondary progressive MS (SPMS) or primary progressive MS (PPMS)

          -  Prior use of disease modifying drugs (DMDs) within the last 3 months, or 2 or more
             prior treatment failures with DMDs on the basis of efficacy

          -  Has significant leukopenia (white blood cell count less than 0.5 times the lower limit
             of normal of the central laboratory) within 28 days prior to Study Day 1

          -  Has received cladribine, mitoxantrone, total lymphoid irradiation, myelosuppressive
             therapy, campath-1h, cyclophosphamide, azathioprine, methotrexate or natalizumab

          -  Has received oral or systemic corticosteroids or adrenocorticotropic hormone within 28
             days prior to Study Day 1

          -  Has compromised immune function or infection

          -  Has received oral or systemic corticosteroids or adrenocorticotropic hormone within 28
             days prior to Study Day 1

          -  Has received cytokine-based therapy, intravenous immunoglobulin therapy, or
             plasmapheresis within 3 months prior to Study Day 1

          -  Has platelet and absolute neutrophil counts below the lower limit of normal range
             within 28 days prior to Study Day 1

          -  Has prior or current history of malignancy

          -  Has a history of persistent anemia, leukopenia, neutropenia, or thrombocytopenia after
             immunosuppressive therapy

          -  Has systemic disease that, in the opinion of the Investigator, might interfere with
             subject safety, compliance or evaluation of the condition under Study (for example,
             insulin-dependent diabetes, Lyme disease, clinically significant cardiac, hepatic, or
             renal disease, Human Immunodeficiency Virus, or Human T-Cell Lymphotrophic Virus
             Type-1)

          -  Has a psychiatric disorder that, in the opinion of the Investigator, was unstable or
             would preclude safe participation in the study

          -  Has allergy or hypersensitivity to gadolinium, to cladribine or any of its excipients

          -  Has used any investigational drug or experimental procedure within 6 months prior to
             Study Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J. Greenberg, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Switzerland</country>
  </removed_countries>
  <results_reference>
    <citation>Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg SÃ¸rensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.</citation>
    <PMID>20089960</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>September 30, 2013</results_first_submitted>
  <results_first_submitted_qc>September 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2013</results_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cladribine 5.25 mg/kg</title>
          <description>Cladribine tablet administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Cladribine 3.5 mg/kg</title>
          <description>Cladribine tablet administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 and placebo matched to cladribine tablet was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo matched to cladribine tablet administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="456"/>
                <participants group_id="P2" count="433"/>
                <participants group_id="P3" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="406"/>
                <participants group_id="P2" count="398"/>
                <participants group_id="P3" count="380"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cladribine 5.25 mg/kg</title>
          <description>Cladribine tablet administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Cladribine 3.5 mg/kg</title>
          <description>Cladribine tablet administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 and placebo matched to cladribine tablet was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo matched to cladribine tablet administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="456"/>
            <count group_id="B2" value="433"/>
            <count group_id="B3" value="437"/>
            <count group_id="B4" value="1326"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="9.9"/>
                    <measurement group_id="B2" value="37.9" spread="10.3"/>
                    <measurement group_id="B3" value="38.7" spread="9.9"/>
                    <measurement group_id="B4" value="38.6" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="298"/>
                    <measurement group_id="B3" value="288"/>
                    <measurement group_id="B4" value="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Qualifying Relapse Rate</title>
        <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
        <time_frame>Week 96</time_frame>
        <population>The intention-to-treat (ITT) population included all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 and placebo matched to cladribine tablet was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to cladribine tablet administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Qualifying Relapse Rate</title>
          <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
          <population>The intention-to-treat (ITT) population included all participants who were randomized in the study.</population>
          <units>relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.58" lower_limit="0.12" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.14" spread="0.59" lower_limit="0.12" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.33" spread="0.88" lower_limit="0.29" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wald Chi-square test</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wald Chi-square test</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Relapse-free Participants</title>
        <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the EDSS or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
        <time_frame>Week 96</time_frame>
        <population>The ITT population included all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 and placebo matched to cladribine tablet was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to cladribine tablet administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Relapse-free Participants</title>
          <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the EDSS or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
          <population>The ITT population included all participants who were randomized in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9"/>
                    <measurement group_id="O2" value="79.7"/>
                    <measurement group_id="O3" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disability Progression</title>
        <description>Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Tenth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve.</description>
        <time_frame>Baseline up to Week 96</time_frame>
        <population>The ITT population included all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 and placebo matched to cladribine tablet was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to cladribine tablet administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disability Progression</title>
          <description>Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Tenth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve.</description>
          <population>The ITT population included all participants who were randomized in the study.</population>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Combined Unique (CU) Lesions, Active Time Constant 2 (T2) Lesions, and Active Time Constant 1 (T1) Gadolinium-Enhanced (Gd+) Lesions Per Participant Per Scan</title>
        <description>Mean Number of CU lesions, active T2 lesions, and active T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>Week 96</time_frame>
        <population>The ITT population included all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine 5.25 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg</title>
            <description>Cladribine tablet administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 and placebo matched to cladribine tablet was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to cladribine tablet administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Combined Unique (CU) Lesions, Active Time Constant 2 (T2) Lesions, and Active Time Constant 1 (T1) Gadolinium-Enhanced (Gd+) Lesions Per Participant Per Scan</title>
          <description>Mean Number of CU lesions, active T2 lesions, and active T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>The ITT population included all participants who were randomized in the study.</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CU lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.08"/>
                    <measurement group_id="O2" value="0.43" spread="0.08"/>
                    <measurement group_id="O3" value="1.72" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active T1 Gd+ lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.05"/>
                    <measurement group_id="O2" value="0.12" spread="0.05"/>
                    <measurement group_id="O3" value="0.91" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active T2 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.06"/>
                    <measurement group_id="O2" value="0.38" spread="0.07"/>
                    <measurement group_id="O3" value="1.43" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 96</time_frame>
      <desc>Safety population included all the randomized participants who received at least one dose of stud medication with follow-up safety data</desc>
      <group_list>
        <group group_id="E1">
          <title>Cladribine 5.25 mg/kg</title>
          <description>Cladribine tablet administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Cladribine 3.5 mg/kg</title>
          <description>Cladribine tablet administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 and placebo matched to cladribine tablet was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo matched to cladribine tablet administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cardiac hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Adnexitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Actinomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Myocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Facial spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="324" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="286" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="242" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="430"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

